Ask AI
ProCE Banner Activity

Nursing Management of Adverse Events With Oral Targeted Therapies for HR+/HER2− Breast Cancer: A Pocket Guide

PDF

As oral targeted treatment options for HR-positive/HER2-negative breast cancer continue to expand, nurses need practical, straightforward guidance to recognize and manage complex and overlapping adverse events, support adherence, and maximize treatment benefit. This downloadable point-of-care pocket guide summarizes the indications, dosing, and administration of approved targeted agents, along with recommended strategies for adverse event monitoring and management.

Released: September 18, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Stemline Therapeutics, Inc.

AstraZeneca

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncology nurses and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify and manage toxicities associated with targeted agents in HR-positive/HER2-negative breast cancer, applying strategies to mitigate these adverse events effectively

  • Educate patients, caregivers, and the multidisciplinary team on evidence-based approaches for monitoring and managing adverse events associated with oral targeted therapies for HR-positive/HER2-negative breast cancer

  • Support adherence/persistence to oral targeted therapies in patients with HR-positive/HER2-negative breast cancer through expert-recommended communication strategies, tools, and resources

Financial Disclosures

Primary Author

Ashley Martinez, PhD, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC: consultant/advisor/speaker: Curio.

Kimberly Podsada, MSN, NP-C, CNS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Pfizer.